Recent studies on Tixel use for skin improvement:
The Efficacy of Thermal Mechanical Fractional Injury System for Facial Rejuvenation: Subjective, Objective and Image Analysis Study
J Cosmet Dermatol. 2025 Feb;24(2):e70063. doi: 10.1111/jocd.70063. (Open Access)
Background: Facial aging is the result of a number of factors, including the resorption of skeletal tissue, the atrophy of fat pads, and the laxity of connective tissue. These factors contribute to a reduction in facial volume and the development of skin changes. Thermal mechanical fractional injury (TMFI) represents a minimally invasive solution, stimulating collagen production and enhancing the delivery of topical formulations via epidermal microcraters.
Aim: This study seeks to evaluate the effects of TMFI on skin quality and introduce quantifiable methods to assess improvements.
Patients and methods: Adult patients seeking facial rejuvenation underwent three TMFI sessions, with a one-month interval between each session. The assessment of skin quality was conducted using the Scientific Assessment Scale of Skin Quality (SASSQ), which was completed by blinded experts. Patient satisfaction was evaluated using the FACEQ scale. Additionally, objective texture analysis was performed using the MAZDA program, which quantified surface irregularities.
Results: The objective assessments demonstrated statistically significant improvements in the following parameters: roughness, wrinkles, pore size, elasticity, pigmentation, and erythema (p < 0.001). The FACE-Q results demonstrated high patient satisfaction, with a response rate of 68.4%. The MAZDA analysis confirmed significant texture improvements across most facial zones, with the exception of the medial forehead.
Conclusions: The findings of this study indicate that TMFI is an effective intervention for improving skin quality in a diverse range of patients. This study contributes to the existing literature on TMFI, which supports its use as a valuable tool in the field of skin rejuvenation.
Clinical Efficacy and Safety of a Thermomechanical Fractional Injury Device for Neck Rejuvenation
Abstract
Background: Neck rejuvenation has consistently become a popular cosmetic procedure. While various treatment modalities have been used, a novel fractional thermomechanical skin rejuvenation system was recently developed to create dermal coagulation through direct heat transfer with subsequent neocollagenesis.
Objective: A prospective clinical trial evaluated the efficacy and safety of a thermomechanical fractional injury device (Tixel 2, Novoxel, Netanya, Israel) for neck rhytides.
Materials and methods: Subjects with moderate to severe neck rhytides were enrolled for 4 monthly treatments.
Results: Twenty-six subjects were enrolled and completed all study visits. The mean age was 58.4 years, and 100.0% were women. Fitzpatrick skin types I to IV were included. For Fitzpatrick Wrinkle Classification System (FWCS), the mean baseline score was 6.3. As per investigator, there was a mean 1.5-grade improvement in FWCS at 1-month follow-up ( p < .00001) and 1.4-grade improvement in FWCS at 3-month follow-up ( p < .00001). For physician Global Aesthetic Improvement Scale, all subjects (100%) had improvement at both 1- and 3-month follow-up visits. There were no severe adverse events, and subjects experienced minimal pain.
Conclusion: A novel thermomechanical fractional injury device is effective and safe for the treatment of neck rhytides.
Comprehensive Review of Thermomechanical Fractional Injury Device: Applications in Medical and Cosmetic Dermatology
Objective: Our aim was to review the current and emerging dermatological applications of the novel thermomechanical fractional injury (TMFI) device, Tixel® (Novoxel, Netanya, Israel).
Methods: A systematic review of PubMed using the search terms of “Tixel”, “thermomechanical fractional”, [“thermomechanical ablation” and “skin”], and [“thermomechanical ablation” and “dermatology”].
Results: Thirty-six articles matched our inquiry. Fifteen articles did not meet inclusion criteria. Of the remaining 21 articles, eight were related to device-assisted drug delivery, seven related to photoaging, and seven related to scientific/ preclinical exploration. Preclinical studies have shown ablative and non-ablative microchannel formation similar to that of CO₂ laser but without charring, with clinical studies demonstrating efficacy for a wide range of applications including rhytides, hypertrophic scarring, infantile hemangiomas, and acne/rosacea. The treatment is well tolerated with minimal discomfort and downtime, showing promise for pain-averse and pediatric populations. Few adverse events have been reported, with a high degree of safety demonstrated in all Fitzpatrick types.
Limitations: Heterogeneous result reporting among studies. Limited number of randomized controlled trials.
Conclusion: Tixel® is an emerging TMFI device with a wide range of current and potential applications, including device-assisted drug delivery and treatment of rhytides, photoaging, and scars among other conditions. The device has both ablative and non-ablative settings and has been safely used in all Fitzpatrick skin types. Larger and randomized controlled trials are needed to compare this device to current standard of care treatments.
and
Retrospective study on the safety and tolerability of clinical treatments with a novel Thermomechanical Ablation device on 150 patients
Introduction: There are currently not many publications on the safety of thermomechanical ablation (TMA) devices, and those that are published only have small numbers of subjects. This treatment is gaining popularity in Europe and Asia, and thus there is a need to look at the safety of this treatment.
Objective: The purpose of this retrospective study was to evaluate the safety of the clinical use of the novel TMA system (Tixel, Novoxel, Israel) for facial rejuvenation and treatment of acne scars.
Methods: We did a retrospective review of our first 150 patients who were treated with the TMA device.
Results: One hundred and fifty consecutive patients aged 20 years to 82 years with Fitzpatrick skin types I to V treated with the TMA device were included in this study. The total number of treatment sessions was 327 (average 2.18 treatment per patient). The total number of pulses delivered to these patients was 1 48 856 (average 455 pulses per session). The indications for the treatment were photodamaged skin (n=145) and acne scarring (n=5). All patients were able to use makeup immediately after the treatment at lower settings, thus needing no real recovery time. Patients treated at higher settings were able to use makeup after 2 days. There were four reported complications: post-inflammatory hyperpigmentation (n=2), impetigo (n=1), and dermatitis (n=1).
Conclusions: Using the TMA device in the treatment of photodamage and acne scarring is safe in skin types I to V and has a low incidence of temporary side effects with no permanent side effects.